Abivax S.A.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Abivax S.A. (ABVX) is a clinical-stage biotechnology company that develops therapeutics harnessing the body's natural regulatory mechanisms, particularly through enhanced expression of microRNA-124, to stabilize immune responses in patients with chronic inflammatory diseases; its lead product candidate, obefazimod (formerly ABX464), is an investigational oral small molecule in Phase 3 clinical trials for moderately to severely active ulcerative colitis under the ABTECT program and in Phase 2 development for Crohn's disease under the ENHANCE-CD program; the company also maintains a proprietary chemical library for discovering follow-on drug candidates targeting additional inflammatory indications. Founded in 2013 and headquartered in Paris, France, with research and development facilities in Montpellier, France, and a U.S. office in Waltham, Massachusetts, Abivax operates globally across North America, Europe, Latin America, and Asia Pacific through its clinical trial network spanning over 600 sites in 36 countries. In recent developments, Abivax announced positive top-line results from the 8-week induction trials of obefazimod in ulcerative colitis in Q3 2025, with 44-week maintenance data expected in Q2 2026; completed a $747.5 million public offering in July 2025 to extend its cash runway into Q4 2027; initiated patient enrollment for the ENHANCE-CD Crohn's disease trial in Q3 2024 with data anticipated in 2H 2026; and reduced debt through conversions including EUR 21.9 million from Heights Capital Management post-H1 2025.
Abivax Shares Continue Climbing After Biotech Firm Moves to Bolster Balance Sheet
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax nears $11 billion valuation after fundraising eases M&A pressure
Correction: Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax announces trading resumption of its ordinary shares on Euronext Paris
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris
Abivax Announces Launch of Public Offering of American Depositary Shares
Abivax shares jump as updated trial data eases safety concerns
Abivax shares jump as updated trial data eases safety concerns
French biotech stock soars 25% after new data on experimental medicine
ABIVAX Société Anonyme (ABVX) Discusses ABTECT Maintenance Part 2 Results and Updated Obefazimod Safety and Efficacy Data in Ulcerative Colitis Transcript
Abivax inflammatory bowel drug shows benefit in relapsed and non-responding patients
Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory Ulcerative Colitis Patients and Strengthening the Phase 3 Maintenance Safety Database
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
ABVX DEADLINE: The Gross Law Firm Reminds ABIVAX Societe Anonyme Investors of Upcoming Securities Class Action Deadline
ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against ABIVAX Societe Anonyme (ABVX)